Holen Sie sich die Stockscreener-App
4.58
8.03%
-0.40
Schlusskurs vom Vortag:
$4.98
Offen:
$5.02
24-Stunden-Volumen:
71,553
Relative Volume:
0.55
Marktkapitalisierung:
$255.30M
Einnahmen:
$34.16M
Nettoeinkommen (Verlust:
$-98.43M
KGV:
-1.9573
EPS:
-2.34
Netto-Cashflow:
$-119.33M
1W Leistung:
-8.22%
1M Leistung:
-6.34%
6M Leistung:
-3.58%
1J Leistung:
-12.60%
1-Tages-Spanne:
$4.475
$5.02
1-Wochen-Bereich:
$4.475
$5.24
52-Wochen-Spanne:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Vergleichen Sie FHTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.58 | 273.13M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Published on: 2025-08-10 22:12:46 - Newser
Using data filters to optimize entry into Foghorn Therapeutics Inc.Trading Opportunities Forecast by AI Insight - Newser
Foghorn Therapeutics Inc.’s volatility index tracking explainedFree Watchlist for Low Risk High Return - Newser
Can technical indicators confirm Foghorn Therapeutics Inc.’s reversalStock Market Watch with Smart Filters - Newser
Research Analysts Offer Predictions for FHTX Q3 Earnings - Defense World
Applying Wyckoff theory to Foghorn Therapeutics Inc. stockIntraday Signal Forecast for Fast Traders - Newser
Understanding Foghorn Therapeutics Inc.’s price movementWeekly Hot Stocks Based on Volume Flow - Newser
Will Foghorn Therapeutics Inc. bounce back from current supportAI Driven Swing Trade Forecasting Insight - Newser
Sentiment analysis tools applied to Foghorn Therapeutics Inc.Entry Optimization Guide with Volume Analysis - Newser
Real time alert setup for Foghorn Therapeutics Inc. performanceShort-Term Bounce Forecast for Oversold Stocks - Newser
Top Risks to Consider Before Buying Foghorn Therapeutics Inc. StockChart Scanner for Swing Trade Timing - Newser
What high frequency data says about Foghorn Therapeutics Inc.Free Entry Alert With Low Drawdown Strategy - Newser
How to escape a deep drawdown in Foghorn Therapeutics Inc.Technical Reversal Pattern Summary and Tracker - Newser
Can volume confirm reversal in Foghorn Therapeutics Inc.Value Holding Return Summary With Outlook - Newser
Leading vs lagging indicators on Foghorn Therapeutics Inc. performanceSecure Entry Point Finder with Analysis - Newser
Using portfolio simulators with Foghorn Therapeutics Inc. includedPredictive AI Engine for Smart Investing - Newser
Published on: 2025-08-09 01:18:22 - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilitySteady Return Plan Based on Data Analysis - Newser
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing - Yahoo Finance
Is Foghorn Therapeutics Inc. stock ready for a breakoutLow Volatility Stock Analysis With Confidence - Newser
Wedbush Research Analysts Boost Earnings Estimates for FHTX - Defense World
How to recover losses in Foghorn Therapeutics Inc. stockSafe Entry Screening with Data Backed Analysis - Newser
Foghorn Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayHigh Conviction Stock Long-Term Summary - Newser
Is Foghorn Therapeutics Inc. trending in predictive chart modelsFree Community Strategy With High Win Rate - Newser
Q1 Earnings Estimate for FHTX Issued By Wedbush - Defense World
Foghorn Therapeutics (FHTX) Expected to Announce Earnings on Thursday - Defense World
Foghorn Therapeutics Inc. stock prediction for this weekLong Term Stock Growth Plan Suggestions - Newser
Foghorn 2025 Q2 Earnings Narrowed Losses, 21.9% Net Income Improvement - AInvest
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates - MSN
Foghorn Therapeutics Reports Q2 2025 Financial Results - TipRanks
Is Foghorn Therapeutics Inc. meeting your algorithmic filter criteriaDaily Technical Forecast for Quick Gains - Newser
Foghorn Therapeutics Inc (FHTX) Q2 2025 Earnings: EPS of -$0.33 - GuruFocus
Foghorn Therapeutics Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2025 - MarketScreener
Foghorn Therapeutics Reports Q2 2025 Financial Update - TipRanks
FHTX Reports Strong Q2 Revenue and Advances Cancer Treatment Pip - GuruFocus
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Invest In Growth? - uk.finance.yahoo.com
Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView
Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows - MarketScreener
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update - The Manila Times
Foghorn Reports Major Progress in Lung Cancer Drug Trial, Multiple Pipeline Developments Advance - Stock Titan
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):